RecruitingPhase 3NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Bakersfield, CA · Berkeley, CA · Beverly Hills, CA · +173 more sites